TRGNF Stock - Transgene S.A.
Unlock GoAI Insights for TRGNF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.35M | $7.90M | $3.13M | $9.99M | $2.98M |
| Gross Profit | $-27,925,000 | $-21,688,000 | $-29,042,000 | $-22,890,000 | $-24,365,000 |
| Gross Margin | -439.6% | -274.5% | -929.0% | -229.1% | -817.3% |
| Operating Income | $-35,658,000 | $-30,047,000 | $-29,904,000 | $-23,525,000 | $-23,993,000 |
| Net Income | $-33,971,000 | $-22,328,000 | $-32,810,000 | $-20,004,000 | $-18,450,000 |
| Net Margin | -534.7% | -282.6% | -1049.6% | -200.2% | -618.9% |
| EPS | $-0.34 | $-0.22 | $-0.33 | $-0.22 | $-0.22 |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Visit WebsiteEarnings History & Surprises
TRGNFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q3 2025 | Sep 16, 2025 | — | $-0.17 | — | — |
Q2 2025 | Apr 24, 2025 | — | $-0.18 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-0.18 | — | — |
Q2 2024 | May 14, 2024 | $-0.24 | $-0.07 | +71.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.23 | $-0.17 | +24.1% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.26 | $-0.19 | +26.6% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | — | $-0.16 | — | — |
Q2 2022 | May 10, 2022 | — | $-0.09 | — | — |
Q4 2021 | Nov 4, 2021 | — | $-0.17 | — | — |
Q2 2021 | Apr 27, 2021 | — | $-0.22 | — | — |
Q3 2020 | Sep 16, 2020 | — | $-0.03 | — | — |
Q2 2020 | May 6, 2020 | — | $-0.04 | — | — |
Q4 2019 | Nov 14, 2019 | — | $-0.28 | — | — |
Q2 2019 | May 13, 2019 | — | $0.45 | — | — |
Q3 2018 | Sep 19, 2018 | — | $-0.28 | — | — |
Q1 2018 | Mar 21, 2018 | — | $-0.24 | — | — |
Q4 2017 | Oct 19, 2017 | — | $-0.38 | — | — |
Q1 2017 | Mar 20, 2017 | — | $-0.18 | — | — |
Q3 2016 | Sep 5, 2016 | — | $-0.34 | — | — |
Latest News
Frequently Asked Questions about TRGNF
What is TRGNF's current stock price?
What is the analyst price target for TRGNF?
What sector is Transgene S.A. in?
What is TRGNF's market cap?
Does TRGNF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TRGNF for comparison